The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance) Aggarwal, Rahul , Halabi, Susan , Kelly, William Kevin ... - - Cancer - 2013 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. ... - - JAMA Oncol - 2017 Manuscript - Secondary-not-in-original - Meta-Analysis - Health Outcome - CALGB-30607 , CALGB-30610 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-70501 , CALGB-70604 , CALGB-80405 , CALGB-90401
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer Halabi, Susan , Kelly, William Kevin , Ma, Hua , Zhou, Haojin ... - - J. Clin. Oncol - 2016 Manuscript - Secondary-not-in-original - Comprehensive - GU - CALGB-90601
The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. Halabi, Susan , Kelly, William Kevin , Zhou, Haojin ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Meta-Analysis - GU - CALGB-90401 , S9916
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy Hertz, Daniel L. , Owzar, Kouros , Lessans, Sherrie , Wing, Claudia ... - - Clin. Cancer Res. - 2016 Manuscript - Primary - Primary - PPP - CALGB-60404 , CALGB-90401
A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). Hertz, Daniel Louis , Jiang, Chen , Owzar, Kouros , Halabi, Susan ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - PPP - CALGB-60404 , CALGB-90401
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401 Kelly, William Kevin , Halabi, Susan , Carducci, Michael ... - - J. Clin. Oncol - 2012 Manuscript - Primary - Primary - GU - CALGB-90401
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Kelly, William Kevin , Halabi, Susan , Elfiky, Aymen , Ou, San-San ... - - Cancer - 2008 Manuscript - Primary - Primary - GU - CALGB-99811
Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) Li, Megan , Mulkey, Flora , Jiang, Chen , O’Neil, Bert H. ... - - Clin. Cancer Res. - 2018 Manuscript - Secondary-not-in-original - Meta-Analysis - PPP - CALGB-40502 , CALGB-80405 , CALGB-90401 , E5103
Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance). Patel, Jai Narendra , Jiang, Chen , Hertz, Daniel Louis ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401
